Precigen, Inc. (PGEN): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biopharmaceutical company tackles urgent diseases with innovative gene and cell therapies? Precigen, Inc. (PGEN), a dedicated discovery and clinical stage company, is doing just that. With a focus on immuno-oncology, autoimmune disorders, and infectious diseases, how does Precigen operate and generate revenue, especially with its recent announcement of full year 2024 financial results and business updates? Keep reading to explore Precigen's history, ownership, mission, operational mechanisms, and revenue streams.

Precigen, Inc. (PGEN) History

Precigen's Founding Timeline

Year established

The company was originally founded in 1998.

Original location

The company's original location was Blacksburg, Virginia.

Founding team members

The founding team members included:

• Dr. Randal J. Kirk

Initial capital/funding

Information regarding the initial capital and funding is not readily available.

Precigen's Evolution Milestones

Precigen's Transformative Moments

• Strategic Shift to Healthcare: The rebranding to Precigen in 2020 marked a pivotal shift towards prioritizing innovative healthcare solutions. This involved focusing resources and expertise on advancing its portfolio of gene and cell therapies.
• Divestiture of Non-Healthcare Assets: The sale of Trans Ova Genetics in 2021 for $170 million demonstrated a commitment to streamlining operations and concentrating on the core mission of developing and commercializing human therapeutics.
• Focus on Clinical Advancement: The company's emphasis on clinical trials and research collaborations, such as the partnership with Baylor College of Medicine, underscores its dedication to translating scientific discoveries into tangible benefits for patients.
• For more information, see: Mission Statement, Vision, & Core Values of Precigen, Inc. (PGEN).

Precigen, Inc. (PGEN) Ownership Structure

The ownership structure of Precigen, Inc. reflects a mix of institutional and individual holdings, which is typical for publicly traded biotechnology companies. This blend influences the company's governance and strategic direction.

Precigen, Inc.'s Current Status

Precigen, Inc. is a publicly traded company, meaning its shares are available for purchase on a stock exchange. As a publicly-held entity, it is subject to regulatory oversight and reporting requirements, including those mandated by the Securities and Exchange Commission (SEC). This status allows the company to raise capital through the issuance of stock and provides liquidity for its investors.

Precigen, Inc.'s Ownership Breakdown

The ownership of Precigen, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders. The following table provides an overview of the ownership percentages:

Precigen, Inc.'s Leadership

The leadership team at Precigen, Inc. is responsible for the strategic direction and operational management of the company. Key figures include:

• Helen Sabzevari, PhD: President and CEO
• Harry Thomasian, CPA: Chief Financial Officer

For additional insights into Precigen, Inc.'s financial standing, consider exploring: Breaking Down Precigen, Inc. (PGEN) Financial Health: Key Insights for Investors

Precigen, Inc. (PGEN) Mission and Values

Precigen, Inc. focuses on developing genetic engineering technologies to improve the lives of patients. The company's core values revolve around innovation, collaboration, and a commitment to addressing significant unmet needs in healthcare and food.

Precigen's Core Purpose

Official mission statement

Precigen’s mission statement is: “To improve lives through the development of innovative gene and cell therapies, and next generation biologics to address unmet needs in cancer, autoimmune disorders, and infectious diseases.”

• Focuses on improving lives through advanced therapies.
• Targets critical areas like cancer, autoimmune disorders, and infectious diseases.
• Emphasizes innovation in gene and cell therapies.

Vision statement

Precigen does not have a formal vision statement. However, the vision can be inferred from the company's activities and goals. Precigen strives to be a leader in the development of innovative gene and cell therapies and next-generation biologics. The company aims to transform the treatment landscape for cancer, autoimmune disorders, and infectious diseases, ultimately improving patient outcomes and quality of life.

• Aims to lead in innovative gene and cell therapies.
• Seeks to transform treatment for major diseases.
• Dedicated to improving patient outcomes and quality of life.

Company slogan/tagline

Precigen does not have a widely publicized official slogan or tagline. Instead, they focus on communicating their mission and values through their actions and scientific contributions. Their commitment to innovation and improving patient lives serves as an unofficial motto, reflecting their dedication to advancing healthcare through genetic engineering.

• No official slogan, but commitment to innovation is central.
• Focus on improving patient lives through genetic engineering.
• Dedication to advancing healthcare solutions.

To delve deeper into Precigen's foundational principles, explore: Mission Statement, Vision, & Core Values of Precigen, Inc. (PGEN).

Precigen, Inc. (PGEN) How It Works

Precigen, Inc. operates as a biopharmaceutical company focused on developing gene and cell therapies to improve patient outcomes in areas with unmet medical needs.

Precigen's Product/Service Portfolio

Precigen's Operational Framework

Precigen's operational framework involves several key steps in developing and commercializing its therapies:

• Research and Development: Focused on advancing its technology platforms and developing novel therapeutic candidates.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its therapies.
• Manufacturing: Producing clinical-grade materials for its clinical trials.
• Partnerships: Collaborating with other companies and institutions to expand its capabilities and accelerate the development of its therapies.

Precigen's Strategic Advantages

Precigen's strategic advantages include:

• Innovative Technology Platforms: Proprietary technology platforms like AdenoVerse, UltraCAR-T, and ActoBiotics offer differentiated approaches to gene and cell therapy.
• Diverse Pipeline: A diverse pipeline of therapeutic candidates targeting various diseases.
• Strategic Partnerships: Strategic collaborations enhance capabilities and expand market reach.

To gain more insights into the investors and stakeholders involved with the company, check out: Exploring Precigen, Inc. (PGEN) Investor Profile: Who’s Buying and Why?

Precigen, Inc. (PGEN) How It Makes Money

Precigen, Inc. primarily generates revenue through the development and commercialization of gene and cell therapies, as well as through its bioproduction and animal health segments.

Precigen's Revenue Breakdown

As of the fiscal year 2024, the company's revenue streams can be broken down as follows:

Precigen's Business Economics

Precigen's business economics are influenced by several key factors:

• Research and Development (R&D) Investment: A significant portion of Precigen's expenses is dedicated to R&D, which is crucial for developing new therapies and technologies. High R&D spending can impact short-term profitability but is essential for long-term growth.
• Intellectual Property: Precigen relies heavily on its intellectual property portfolio. Patents and proprietary technologies provide a competitive advantage and enable the company to secure licensing agreements and collaborations.
• Regulatory Environment: The regulatory landscape for gene and cell therapies is complex and can significantly impact the time and cost required to bring products to market. Regulatory approvals are essential for commercial success.
• Partnerships and Collaborations: Strategic partnerships with other companies and research institutions are vital for sharing development costs, accessing new technologies, and expanding market reach.

Precigen's Financial Performance

Key aspects of Precigen's financial performance include:

• Revenue Growth: Monitoring the growth rate of different revenue streams (product sales, licensing, and services) is essential for assessing the company's overall performance.
• Gross Margin: The gross margin reflects the profitability of Precigen's products and services. A higher gross margin indicates greater efficiency in managing production and service costs.
• Operating Expenses: Analyzing operating expenses, including R&D and SG&A (selling, general, and administrative) expenses, helps to understand how efficiently the company is managing its resources.
• Cash Flow: Tracking cash flow from operations, investing, and financing activities provides insights into the company's ability to fund its operations and invest in future growth.
• Net Income/Loss: The bottom line, net income or loss, indicates the company's overall profitability. It is crucial to consider both GAAP (Generally Accepted Accounting Principles) and non-GAAP measures to get a comprehensive view.

To gain further insights into Precigen's mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Precigen, Inc. (PGEN).

Precigen, Inc. (PGEN) Market Position & Future Outlook

As of April 2025, Precigen, Inc. is navigating a dynamic market landscape, focusing on advancing its gene and cell therapy technologies. The company's future outlook hinges on the successful clinical development and commercialization of its innovative therapies, while also managing the inherent risks associated with the biotechnology industry.

Competitive Landscape

Note: Market share percentages are approximate and based on the broader cell and gene therapy market, which is subject to change.

Opportunities & Challenges

Industry Position

Precigen, Inc. operates within the highly competitive and rapidly evolving biotechnology sector, specifically focusing on cell and gene therapies. Here are some key aspects of its industry position:

• Innovative Technology Platforms: The company's AdenoVerse™ and UltraPorator™ technologies provide a foundation for developing novel therapies, offering potential advantages in terms of efficacy and safety.
• Focus on Unmet Medical Needs: Precigen is targeting cancers and other diseases with significant unmet medical needs, which presents both an opportunity and a challenge.
• Strategic Collaborations: Forming strategic alliances with other companies and institutions can help Precigen expand its reach and accelerate the development of its therapies.

To gain a deeper understanding of the company's financial standing, consider exploring this resource: Breaking Down Precigen, Inc. (PGEN) Financial Health: Key Insights for Investors.